Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 3, 2007, Pages 257-263

  Klammt, Sebastian ^a   Mitzner, Steffen ^a   Stange, Jan ^a   Brinkmann, Beate ^a   Drewelow, Bernd ^a   Emmrich, Jörg ^a   Liebe, Stefan ^a   Schmidt, Reinhard ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin binding; Albumin binding capacity; Albumin bound substances; Liver cirrhosis; Model for end stage liver disease

Indexed keywords

DANSYLSARCOSINE; DIAZEPAM; HUMAN SERUM ALBUMIN; SARCOSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; LIGAND BINDING; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; ONCOTIC PRESSURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TRANSPORT; SCORING SYSTEM;

ADULT; AGED; BILIRUBIN; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

EID: 33847015247     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3280101f7d     Document Type: Article

References (40)

1. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41:1211-1219.
2. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409.
3. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941-948.
4. Fernandez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42:627-634.
5. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002; 25:695-704.
6. Sudlow G, Birkett DJ,Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976; 12:1052-1061.
7. Sudlow G, Birkett DJ,Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975; 11:824-832.
8. Peters T. All about albumin. San Diego, California: Academic Press Inc.; 1996.
9. Hughes RD. Review of methods to remove protein-bound substances in liver failure. Int J Artif Organs 2002; 25:911-917.
10. Venturini I, Corsi L, Avallone R, Farina F, Bedogni G, Baraldi C, et al. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. Scand J Gastroenterol 2001; 36:423-425.
11. Barbare JC, Poupon RE, Jaillon P, Prod'homme S, Darnis F, Poupon RY. Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis. J Hepatol 1985; 1:253-259.
12. Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001; 70:425-430.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
14. Kamath PS,Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
15. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transplant 2001; 7:567-580.
16. Kober A, Jenner A, Sjoholm I. Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin. Biochem Pharmacol 1978; 27:2729-2735.
17. Greco AV, Mingrone G, Favuzzi A, Bertuzzi A, Gandolfi A, DeSmet R, et al. Subclinical hepatic encephalopathy: role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Invest Med 2000; 48: 274-280.
18. Klammt S, Brinkmann B, Mitzner SR, Munzert E, Loock J, Stange J, et al. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol 2001; 39:24-27.
19. UNOS. UNOS Policy 3.6.4. [6/24/2005]. 2005.
20. Keller E, Beeser H, Peter HH, Arnold A, Kotitschke R. Comparison of fresh frozen plasma with a standardized serum protein solution following therapeutic plasma exchange in patients with autoimmune disease: a prospective controlled clinical trial. Ther Apheresis 2000; 4: 332-337.
21. Odell GB, Cohen SN, Kelly PC. Studies in kernicterus. II. the determination of the saturation of serum albumin with bilirubin. J Pediatr 1969; 74: 214-230.
22. Porter EG, Waters WJ. A rapid micromethod for measuring the reserve albumin binding capacity in serum from newborn infants with hyperbilirubinemia. J Lab Clin Med 1966; 67:660-668.
23. Matthes G, Seibt G, Muravsky V, Hersmann G, Dornheim G. Albumin transport analysis of different collected and processed plasma products by electron spin resonance spectroscopy. Transfus Apheresis Sci 2002; 27:129-135.
24. Muravskaya EV, Lapko AG, Muravskii VA. Modification of transport function of plasma albumin during atherosclerosis and diabetes mellitus. Bull Exp Biol Med 2003; 135:433-435.
25. Sarnatskaya VV, Lindup WE, Ivanov AI, Yushko LA, Tjia J, Maslenny VN, et al. Extraction of uraemic toxins with activated carbon restores the functional properties of albumin. Nephron Physiol 2003; 95:10-18.
26. Menke G, Worner W, Kratzer W, Rietbrock N. Kinetics of drug binding to human serum albumin: allosteric and competitive inhibition at the benzodiazepine binding site by free fatty acids of various chain lengths. Naunyn Schmiedebergs Arch Pharmacol 1989; 339:42-47.
27. Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut 2004; 53:890-898.
28. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12:S75-S82.
29. Adler M, Verset D, Bouhdid H, Bourgeois N, Gulbis B, Le MO, et al. Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score. J Hepatol 1997; 26:642-649.
30. Ceryak S, Bouscarel B, Malavolti M, Fromm H. Extrahepatic deposition and cytotoxicity of lithocholic acid: studies in two hamster models of hepatic failure and in cultured human fibroblasts. Hepatology 1998; 27:546-556.
31. Lozeva V, Montgomery JA, Tuomisto L, Rocheleau B, Pannunzio M, Huet PM, et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004; 40:742-748.
32. Avallone R, Zeneroli ML, Venturini I, Corsi L, Schreier P, Kleinschnitz M, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut 1998; 42:861-867.
33. Rabinowitz JL, Staeffen J, Aumonier P, Ballan P, Ferrer J, Terme R, et al. A method for serum octanoate in hepatic cirrhosis and hepatic encephalopathy. Clin Chem 1977; 23:2202-2206.
34. Cheruvallath VK, Riley CM, Narayanan SR, Lindenbaum S, Perrin JH. The effect of octanoic acid on the binding of the enantiomers of ibuprofen and naproxen to human serum albumin: a chromatographic implication. Pharm Res 1996; 13:173-178.
35. Olsen H, Andersen A, Nordbo A, Kongsgaard UE, Bormer OP. Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin Pharmacol 2004; 4:4.
36. Douglass A, Al MH, Record CO. Oral tryptophan challenge studies in cirrhotic patients: no evidence of neuropsychiatric changes. Metab Brain Dis 2003; 18:179-186.
37. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998; 28:374-378.
38. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41:353-358.
39. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129: 1944-1953.
40. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005; 42 (Suppl 1):S100-S107.